GlobeNewswire Inc.··Greenwich Lifesciences, Inc.Greenwich LifeSciences Doubles Market for GP2 Cancer Therapy With Expanded Patent Claims
Greenwich LifeSciences expands GLSI-100 breast cancer therapy addressable market by 100% through new patent claims extending to 2045, adding 88,000 potential patients annually.
GLSIGLSI-100FLAMINGO-01